Clinical evaluation of the efficacy of the P2X7purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine (Q57231903)
scholarly article by Edward C Keystone et al published 10 September 2012 in Annals of the Rheumatic Diseases
Language:
Current Data About Clinical evaluation of the efficacy of the P2X7purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine
(P31) (Q13442814)

(P50) (Q41687181)
(P1932) Iain B McInnes
(P1545) 5

(P304) 1630-1635

(P407) (Q1860)

(P433) 10

(P478) 71

(P577) Monday, September 10, 2012

(P921) (Q181600)

(Q187255)
(P887)

(Q422232)
(P887)

(P1433) (Q4767876)

(P1476) "Clinical evaluation of the efficacy of the P2X7purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine" (language: en)

(P2093) Edward C Keystone
(P1545) 1

Millie M Wang
(P1545) 2

Mark Layton
(P1545) 3

Sally Hollis
(P1545) 4

other details
description scholarly article by Edward C Keystone et al published 10 September 2012 in Annals of the Rheumatic Diseases

External Links
(P356) 10.1136/ANNRHEUMDIS-2011-143578
(P698) 22966146